Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography

In Vivo

Volumn 19, Issue 3, 2005, Pages 567-576

  Pichon, M F ^a   Cvitkovic, F ^a   Hacene, K ^a   Delaunay, J ^a   Lokiec, F ^a   Colllignon, M A ^a   Pecking, A P ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Anthracyclines; B type natriuretic peptide; Breast cancer; Radionuclide ventriculography

Indexed keywords

ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOMEGALY; CARDIOPULMONARY INSUFFICIENCY; CARDIOTOXICITY; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HUMAN; IMMUNORADIOMETRIC ASSAY; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PATIENT MONITORING; PILOT STUDY; PLEURA EFFUSION; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIOISOTOPE VENTRICULOGRAPHY; STATISTICAL MODEL; TACHYCARDIA; VEIN THROMBOSIS;

EID: 17644388763     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rosencweig M and Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717, 1979.
2. Buzdar AU, Marcus C, Smith TI and Blumenshein GR: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761-2765, 1985.
3. Nousiainen T, Jantunen E, Vanninen E, Remes J and Vuolteenaho O: Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol 61: 347-353, 1998.
4. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE and Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808-815, 1991.
5. Sorensen K, Levitt GA, Bull K, Dorup I and Sullivan ID: Late anthracycline cardiotoxicity after childood cancer. Cancer 97: 1991-1998, 2003.
6. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ and Keefe D: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221, 2002.
7. Suzuki T, Hayashi D, Yamazaki T, Mizouno T, Kanda Y, Komuro I, Kurabayashi M, Yamaoki K, Mitani K, Hiari H, Nagai R and Yazaki Y: Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136: 362-363, 1998.
8. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O and Hartikainen J: Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 62: 135-141, 1999.
9. Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, Ikeno A, Usuda K, Ishikawa T, Ohtake S and Matsuda T: Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104: 158-163, 2000.
10. Ciotti R, Ucci G, Belotti G, Facchi E, Cremonesi M, Gatti C and Baccheta G: Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it? J Clin Oncol 19: 4269-4270, 2001.
11. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M and Sakurai M: Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 37: 4-9, 2001.
12. Meinardi MT, Van Veldhuisen DJ, Gietema JA, Dolsma VW, Boosma F, Van Den Berg NP, Volkers C, Haaksma J, De Vries EGE, Sliejfer DT and Van Der Graaf WTA: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19: 2746-2753, 2001.
13. Okada Y, Horikawa K and Sano M: Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy. Gan To Kagaku Ryoko 24: 585-589, 1997.
14. Robert J: Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45(suppl. 2): 20-30, 1993.
15. Bourguignon MH, Douglass KH, Links JM and Wagner HN Jr: Fully automated data acquisition, processing, and display in equilibrium radioventriculography. Eur J Nucl Med 6: 343-7, 1981.
16. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR and Burnett JC: Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40: 976-982, 2002.
17. Shapiro BP, Chen HH, Burnett JC and Redfield M: Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc 78: 481-486, 2003.
18. Akaike H: A New look at the statistical model identification. IEEE Transactions on Automatic Control AC 19: 716-723, 1974.
19. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C and Cipolla CM: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109 2749-2754, 2004.
20. Sparano JA, Brown DL and Wolff AC: Predicting cancer therapy-induced cardiotoxicity. Drug Saf 25: 302-311, 2002.